-
Subject Areas on Research
-
"Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE Registry.
-
2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery.
-
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
-
2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
-
2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
-
2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society.
-
2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
-
3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
-
A health literacy pilot intervention to improve medication adherence using Meducation® technology.
-
A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study).
-
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction).
-
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).
-
Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial.
-
Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
-
Adenosine for myocardial protection in acute myocardial infarction.
-
Adenosine-induced transient asystole for intracranial aneurysm surgery: a retrospective review.
-
Adherence to Guideline-Recommended Therapy-Including Supervised Exercise Therapy Referral-Across Peripheral Artery Disease Specialty Clinics: Insights From the International PORTRAIT Registry.
-
Adverse drug events in high risk older outpatients.
-
Age and persistent use of cardiovascular medication after acute coronary syndrome: results from medication applied and sustained over time.
-
American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock.
-
Antianginal therapy before percutaneous coronary intervention.
-
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
-
Association of Patient Enrollment in Medicare Part D With Outcomes After Acute Myocardial Infarction.
-
BNP-guided heart failure therapy in older patients.
-
BNP-guided therapy for heart failure.
-
Back to the future: improving the use of guidelines-recommended coronary disease secondary prevention at the dawn of the precision medicine era.
-
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
-
Body surface area and medication dosing in patients with heart failure with reduced ejection fraction.
-
Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications.
-
Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy.
-
Calcineurin signaling in human cardiac hypertrophy.
-
Cardiac allograft vasculopathy: A review.
-
Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction.
-
Cardiovascular Disease and HIV: Pathophysiology, Treatment Considerations, and Nursing Implications.
-
Cardiovascular Drug Pricing: Less Innovation for More Access?
-
Cardiovascular Medications and Fractures: Dodging Complexity.
-
Cardiovascular drug development: is it dead or just hibernating?
-
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
-
Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative).
-
Characteristics and Outcomes of Suspected Digoxin Toxicity and Immune Fab Treatment Over the Past Two Decades-2000-2020.
-
Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis.
-
Clinical application of cardiovascular pharmacogenetics.
-
Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study.
-
Clinical outcomes in real-world patients with bifurcation lesions receiving Xience V everolimus-eluting stents: Four-year results from the Xience V USA study.
-
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
-
Coenzyme Q10 and Heart Failure: A State-of-the-Art Review.
-
Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.
-
Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus.
-
Comparison of medicine alone, coronary angioplasty, and left internal mammary artery-coronary artery bypass for one-vessel proximal left anterior descending coronary artery disease.
-
Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines.
-
Complement activation and cardiac surgery: a novel target for improving outcomes.
-
Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches.
-
Contemporary Applications of Machine Learning for Device Therapy in Heart Failure.
-
Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.
-
Contemporary therapy of acute ST-elevation myocardial infarction.
-
Cost of ventricular assist devices: can we afford the progress?
-
Criteria for dose-finding in two-stage seamless adaptive design.
-
Cumulative Cardiovascular Polypharmacy Is Associated With the Risk of Acute Kidney Injury in Elderly Patients.
-
Current and novel pharmacologic approaches in advanced heart failure.
-
Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
-
Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial.
-
Decongestion in acute heart failure.
-
Determination of the falloff constant (k(f)) from modeling biochemical marker release: a new variable for discriminating therapies.
-
Developing Breakthrough Drugs for Heart Failure: Lessons Learned From the Cystic Fibrosis Experience.
-
Developing New Treatments for Heart Failure: Focus on the Heart.
-
Diagnostic Cardiovascular Imaging and Therapeutic Strategies in Pregnancy: JACC Focus Seminar 4/5.
-
Difference in Medication Adherence Between Patients Prescribed a 30-Day Versus 90-Day Supply After Acute Myocardial Infarction.
-
Disease management of congestive heart failure.
-
Does ranolazine have a place in the treatment of acute coronary syndromes?
-
Doing the right things and doing them the right way: association between hospital guideline adherence, dosing safety, and outcomes among patients with acute coronary syndrome.
-
Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?
-
Drug-induced lung injury.
-
Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM).
-
Economic end points in phase II trials.
-
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis.
-
Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
-
Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease.
-
Effects of Exercise Training With and Without Ranolazine on Peak Oxygen Consumption, Daily Physical Activity, and Quality of Life in Patients With Chronic Stable Angina Pectoris.
-
Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
-
Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.
-
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
-
Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod.
-
Enabling social listening for cardiac safety monitoring: Proceedings from a drug information association-cardiac safety research consortium cosponsored think tank.
-
Endpoints in Heart Failure Drug Development: History and Future.
-
Enhancement of cardiac function by cyclocreatine in models of cardiopulmonary bypass.
-
Enhancement of the force-frequency effect on myocardial contractility by adrenergic stimulation in conscious dogs.
-
Enhancing Cardiac Rehabilitation With Stress Management Training: A Randomized, Clinical Efficacy Trial.
-
Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations.
-
Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs.
-
Evidence-based therapy prescription in high-cardiovascular risk patients: the REACT study.
-
Extended-release ranolazine: critical evaluation of its use in stable angina.
-
Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI.
-
Few Disparities in Baseline Laboratory Testing After the Diuretic or Digoxin Initiation by Medicare Fee-For-Service Beneficiaries.
-
Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial.
-
Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association.
-
G-Protein-Coupled Receptors in Heart Disease.
-
GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs.
-
Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease.
-
Gender differences in the treatment of non-ST-segment elevation myocardial infarction.
-
Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study.
-
Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction.
-
Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals: Findings From Get With The Guidelines-Heart Failure.
-
Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure.
-
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
-
High-resolution CT of drug-induced lung disease.
-
Hospital percutaneous coronary intervention appropriateness and in-hospital procedural outcomes: insights from the NCDR.
-
Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial.
-
ISCHEMIA: Establishing the Primary End Point.
-
Impact of Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices on Posttransplantation Mortality.
-
Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders.
-
Implications of Using Different Definitions on Outcomes in Worsening Heart Failure.
-
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
-
Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy.
-
Indications for pacing in the treatment of bradyarrhythmias. Report of an independent study group.
-
Influence of renal function on the use of guideline-recommended therapies for patients with heart failure.
-
Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly.
-
International variation in the use of evidence-based medicines for acute coronary syndromes.
-
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
-
Intramyocardial, autologous CD34+ cell therapy for refractory angina.
-
Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications.
-
Ischemia change in stable coronary artery disease is an independent predictor of death and myocardial infarction.
-
Issues with care in the elderly patient presenting with acute ischemia.
-
Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
-
Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
-
Lessons learned from clinical trials in acute heart failure: phase 3 drug trials.
-
Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial.
-
Long-Term Mortality of Older Patients With Acute Myocardial Infarction Treated in US Clinical Practice.
-
Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
-
Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.
-
Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy.
-
Lower extremity amputation in peripheral artery disease: improving patient outcomes.
-
Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients.
-
Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry.
-
Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology.
-
Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery ® and the American Venous Forum.
-
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.
-
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
-
Medical and surgical management of coronary artery disease in women.
-
Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures.
-
Medication adherence: a call for action.
-
Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges.
-
Medication non-adherence after myocardial infarction: an exploration of modifying factors.
-
Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007.
-
Metaanalysis and review of heart failure disease management randomized controlled clinical trials.
-
Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
-
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
-
New precompetitive paradigms: focus on cardiac safety.
-
Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.
-
Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.
-
Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection.
-
Outpatient management of heart failure in the United States, 2006-2008.
-
PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories): Overview of Design and Rationale of an International Prospective Peripheral Arterial Disease Study.
-
Paroxysmal high-grade atrioventricular block and syncope in a previously healthy child: what is the mechanism?
-
Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure.
-
Patient management after noninvasive cardiac imaging results from SPARC (Study of myocardial perfusion and coronary anatomy imaging roles in coronary artery disease).
-
Patient-Reported Outcome Measures in Cardiovascular Disease: An Evidence Map of the Psychometric Properties of Health Status Instruments.
-
Patient-centered adherence intervention after acute coronary syndrome hospitalization.
-
Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation.
-
Pediatric cardiovascular drug trials, lessons learned.
-
Percutaneous coronary intervention for older adults who present with syncope and coronary artery disease? Insights from the National Cardiovascular Data Registry.
-
Perioperative Quality Initiative consensus statement on preoperative blood pressure, risk and outcomes for elective surgery.
-
Perioperative management of drug therapy, clinical considerations.
-
Persistence of evidence-based medication use after discharge from academic versus nonacademic hospitals among patients with non-ST-segment elevation myocardial infarction.
-
Personalized Therapeutic Approach: Gun Control for Shotgun Therapy.
-
Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.
-
Pharmacogenetics in heart failure trials.
-
Pharmacological and emerging therapies in the treatment of chronic angina.
-
Pharmacological properties of tropyl benzilate hydrochloride (BAT) and its N-allyl derivative (NTB).
-
Pharmacological therapy for myocardial reperfusion injury.
-
Pharmacotherapy in Older Adults with Cardiovascular Disease: Report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging Workshop.
-
Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association.
-
Pheochromocytoma complicated with cardiomyopathy after delivery--a case report and literature review.
-
PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design.
-
Polypill Trials for Stroke Prevention-Main Results, Critical Appraisal, and Implications for US Population.
-
Porphyrin-Based SOD Mimic MnTnBu OE -2-PyP5+ Inhibits Mechanisms of Aortic Valve Remodeling in Human and Murine Models of Aortic Valve Sclerosis.
-
Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done?
-
Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy.
-
Predictors of contemporary coronary artery bypass grafting outcomes.
-
Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry.
-
Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study.
-
PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial.
-
Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.
-
Process of care performance measures and long-term outcomes in patients hospitalized with heart failure.
-
Provisional stenting versus routine stenting: is it worth the price?
-
Psychometric Properties of the Four-Item Morisky Green Levine Medication Adherence Scale among Atherosclerosis Risk in Communities (ARIC) Study Participants.
-
Public Health Impact of the Centers for Medicare and Medicaid Services Decision on Pass-Through Add-On Payments for Drug-Coated Balloons: A Call to Action.
-
Pulmonary drug toxicity: radiologic and pathologic manifestations.
-
Putting the Acute Coronary Syndrome in Context After 80 Years of Age.
-
Quality of care and in-hospital outcomes in patients with coronary heart disease in rural and urban hospitals (from Get With the Guidelines-Coronary Artery Disease Program).
-
Quantifying the utility of taking pills for cardiovascular prevention.
-
Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey.
-
Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.
-
Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines?).
-
Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.
-
Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME).
-
Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
-
Rationale and Design of the VITALITY-HFpEF Trial.
-
Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations.
-
Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure.
-
Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank.
-
Recurrence of local anesthetic cardiac toxicity or hypokalemia?
-
Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF.
-
Renal function and coronary bypass surgery in patients with ischemic heart failure.
-
Renal function, concomitant medication use and outcomes following acute coronary syndromes.
-
Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study.
-
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
-
Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase.
-
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial.
-
Results of the Chronic Heart Failure Intervention to Improve MEdication Adherence study: A randomized intervention in high-risk patients.
-
SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment): A Prospective, Randomized Trial of CMX-2043 in Patients Undergoing Elective Percutaneous Coronary Intervention.
-
Sample size and interim analysis issues for dose selection.
-
Selection of surgical or percutaneous coronary intervention provides differential longevity benefit.
-
Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.
-
Sex Differential in 15-Hydroxyprostaglandin Dehydrogenase Levels in the Lumen of Human Intracranial Aneurysms.
-
Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes.
-
Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry.
-
Short- and long-term outcomes of coronary stenting in women versus men: results from the National Cardiovascular Data Registry Centers for Medicare & Medicaid services cohort.
-
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
-
Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association.
-
Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium.
-
Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF).
-
Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
-
Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
-
Surgical correction of aortic valve insufficiency after left ventricular assist device implantation.
-
Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study.
-
Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes.
-
Synergistic effects of exposure to concentrated ambient fine pollution particles and nitrogen dioxide in humans.
-
Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does "X" Really Mark the Spot?
-
Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial.
-
Temporal Trends in Utilization of Cardiac Therapies and Outcomes for Myocardial Infarction by Degree of Chronic Kidney Disease: A Report From the NCDR Chest Pain-MI Registry.
-
Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease.
-
The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
-
The Cardiac Safety Research Consortium enters its second decade: An invitation to participate.
-
The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development.
-
The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care.
-
The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.
-
The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction.
-
The clinical evaluation of the Endeavor zotarolimus-eluting coronary stent in Japanese patients with de novo native coronary artery lesions: primary results and 3-year follow-up of the Endeavor Japan study.
-
The disconnect between phase II and phase III trials of drugs for heart failure.
-
The effect of dementia on outcomes and process of care for Medicare beneficiaries admitted with acute myocardial infarction.
-
The impact of medication use in a multicomponent intervention: results from the WISEWOMAN program.
-
The meanings associated with medicines in heart failure patients.
-
The neurohormonal network in the RAAS can bend before breaking.
-
The process of bringing new drug-eluting stents to market will they see the light of day?
-
The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial.
-
The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials.
-
The usage patterns of cardiac bedside markers employing point-of-care testing for troponin in non-ST-segment elevation acute coronary syndrome: results from CRUSADE.
-
The use of vasoactive agents via peripheral intravenous access during transport of critically III infants and children.
-
Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions.
-
Therapy insight: how changes in renal function with increasing age affect cardiovascular drug prescribing.
-
Timing of Postdischarge Follow-Up and Medication Adherence Among Patients With Heart Failure.
-
Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure.
-
Translating the Secondary Prevention Therapeutic Boom Into Action.
-
Translation of acute coronary syndrome therapies: from evidence to routine clinical practice.
-
Treatment of non-ST-elevation acute coronary syndrome in the elderly: current practice and future opportunities.
-
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.
-
Trends in isolated coronary artery bypass grafting: an analysis of the Society of Thoracic Surgeons adult cardiac surgery database.
-
Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration.
-
Update on perioperative care of the cardiac patient for noncardiac surgery.
-
Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease.
-
Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials.
-
Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians.
-
Use of guideline-recommended therapies for heart failure in the Medicare population.
-
Using measures of disease progression to determine therapeutic effect: a sirens' song.
-
What can heart failure trialists learn from oncology trialists?
-
Whatever happened to the polypill?
-
Keywords of People
-
-
Alexander, John Hunter Peel,
Professor of Medicine,
Medicine, Cardiology
-
Cohen-Wolkowiez, Michael,
Professor of Pediatrics,
Pediatrics, Infectious Diseases
-
Curtis, Lesley H.,
Professor in Population Health Sciences,
Medicine, General Internal Medicine
-
O'Connor, Christopher Michael,
Richard Sean Stack, M.D. Distinguished Professor,
Medicine, Clinical Pharmacology